- CEO
- Zheng Jie Wu
- Full Time Employees
- 588
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Linhai China
- IPO Date
- Sep 14, 2021
- Business
- Zhejiang Benli Technology Co., Ltd. is a China-based fine chemical manufacturing enterprise engaged in the research, development, production, and commercialization of advanced pharmaceutical intermediates, agrochemical intermediates, and specialty chemical materials. The company operates primarily through three business segments: Pharmaceutical Intermediates, Agrochemical Intermediates, and Specialty Chemical Products. Its core product portfolio comprises quinolone antibacterial drug intermediates, including ethyl 2,4-dichloro-5-fluorobenzoylacetate (Product 801), ethyl 2-(2,4-dichloro-5-fluorobenzoyl)-3-cyclopropylaminoacrylate (Product 1201), cyclopropylamine, and cyclopropanecarboxylic acid derivatives utilized in the synthesis of fluoroquinolones such as ciprofloxacin, levofloxacin, enrofloxacin, and moxifloxacin; pesticide intermediates, including halogenated and heterocyclic compounds, pyrazole derivatives, and fluorinated benzene intermediates for fungicides, insecticides, and herbicides; and specialty functional chemicals, including cyclopropane series derivatives, aromatic fluorochemicals, and custom chemical building blocks for pharmaceutical synthesis and advanced materials. Zhejiang Benli Technology Co., Ltd. serves pharmaceutical formulation developers, active pharmaceutical ingredient (API) manufacturers, agrochemical producers, and fine chemical distributors across domestic Chinese markets and international regions throughout Asia, Europe, and the Americas. Founded in 2011 and headquartered in Taizhou, Zhejiang Province, China, the company maintains modernized manufacturing facilities, research and development centers, and operating subsidiaries across regional industrial parks. In recent operational developments, the company has advanced the construction and commissioning of green continuous-flow and microchannel synthesis production lines, expanded its capacity for high-value fluorinated and cyclopropane-based intermediates, broadened its custom development and manufacturing (CDMO) services, and deepened strategic supply alliances with leading domestic and multinational crop science and pharmaceutical enterprises to diversify its downstream commercial offerings.